PRINCETON, N.J., Oct. 12, 2023 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic ...
PC14586 targets p53 Y220C mutants to selectively reactivate p53, restoring the protein’s tumor-suppressing function Phase 1/2 study is enrolling patients with advanced solid tumors that have a p53 ...
PMV Pharmaceuticals Inc (NASDAQ:PMVP) announced updated Phase 1 results from its ongoing Phase 1/2 PYNNACLE trial that showed PC14586 achieved efficacy in heavily pretreated patients across multiple ...
PMV Pharmaceuticals has reported a 43% response rate in a midphase ovarian cancer trial, putting the biotech on a track it believes will lead to a filing for FDA approval in the first quarter of 2027.
PRINCETON, N.J., Oct. 11, 2023 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic ...
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It’s lead product ...
Hosted on MSN
PMV Pharmaceuticals stock hits 52-week low at $1.32
In a challenging market environment, PMV Pharmaceuticals Inc. (PMVP) stock has touched a 52-week low, reaching a price level of $1.32. According to InvestingPro data, while the company maintains a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback